- Opinion
- [Reporter's view] Consistency in the post evaluation
- by Lee, Tak-Sun Mar 7, 2022 05:49am
- Re-evaluation of drugs is underway. The move is aimed at preventing waste of health insurance benefits due to insufficient drugs to verify efficacy. Accordingly, the MFDS is playing a leading role in re-evaluating clinical trials and the HIRA is playing a leading role in re-evaluating the adequacy of benefits. The problem is that there is no
- Opinion
- [Reporter’s View] Why Big Pharmas 'select and focus'
- by Mar 2, 2022 05:54am
- In the famous TV show ‘Backstreet,’ CEO Baek Jong-won’s main advice and solution for small eateries suffering from slow business was to ‘reduce menus.’ Paik tells the restaurant owners to concentrate on their main menus instead of trying everything. Due to his consistent act of reducing menus in every restaurant he consults, he was fond
- Opinion
- [Reporter's view]Will it be different this time?
- by Kim, Jin-Gu Feb 23, 2022 05:49am
- Earlier this month, the government announced "Comprehensive Measures for Stable Supply of National Essential Drugs." In the wake of the COVID-19 crisis, the importance of stockpiling and supplying essential medicines has increased, and the government has stepped up. National essential drugs refer to drugs that are essential for health care
- Opinion
- [Reporter’s View] Why set deadlines in pricing negotiations
- by Eo, Yun-Ho Feb 17, 2022 05:53am
- A deadline is a pre-determined set amount of period. If this period is extended frequently, what meaning would setting a ‘deadline’ have? This question arises with the uprise of deadline extensions being made in the drug pricing negotiations between the National Health Insurance Service and pharmaceutical companies for reimbursement lis
- Opinion
- [Reporter's view]Predictability should be increased
- by Lee, Tak-Sun Feb 14, 2022 05:54am
- Starting with Choline Alfoscerate, a brain function improving agent, the benefit reassessment, which has been in full swing since last year, has risen again this year. On the 11th, HIRA's Drug Reimbursement Evaluation Committee confirmed the items subject to salary revaluation in 2022 and 2023. Detailed items will be released through the Heal
- Opinion
- [Desk] 550,000 soldiers and COVID-19 vaccine
- by Nho, Byung Chul Feb 10, 2022 05:54am
- In mid-August last year, the Ministry of National Defense completed the first and second vaccinations against 550,000 soldiers. The types are identified as Moderna and Pfizer vaccines, including the Janssen vaccine. It deserves to be evaluated as a "successful vaccine operation" achieved quickly in a quasi-war situation facing North Korea. Cu
- Opinion
- [Reporter’s View] Mutual understanding is required
- by Kim, Jin-Gu Feb 4, 2022 05:57am
- The National Health Insurance Service made a pre-announcement for the amendment of the detailed guidelines of the ‘Price-Volume Agreement.’ The Price-Volume Agreement, or PVA, is a system that discounts a drug’s price by up to 10% through negotiation between the pharmaceutical company and NHIS for products whose use volume had rapidly
- Opinion
- [Reporter’s View] Ahead Kymriah’s NHIS negotiations
- by Eo, Yun-Ho Jan 28, 2022 05:57am
- Only the National Health Insurance Service left to go, the ultra-high-priced novel CAR-T therapy ‘Kymriah (tisagenlecleucel)’ passed all the steps necessary for insurance benefit. In other words, the fate of Kymriah’s reimbursement now lies The fate of Kymriah’s reimbursement, a drug that costs around &8361;500 million for a singl
- Opinion
- [Desk] The task of reimbursement for ultra-high-priced drugs
- by Kim, Jung-Ju Jan 18, 2022 06:05am
- The evaluation of the adequacy of the super-high-priced Kymriah's benefit is approaching insurance coverage. This is because the agenda to expand the health insurance standards for Kymriah, a treatment for acute lymphocytic leukemia and lymphoma CAR-T, and Keytruda, a non-small cell lung cancer immuno-cancer drug, passed side by side at the H
- Opinion
- [Reporter’s View] Can companies get EUAs as they promised?
- by Lee, Tak-Sun Jan 12, 2022 06:04am
- The Emergency Use Authorization (EUA) system was first introduced to Korea in March last year. AstraZeneca’s COVID-19 vaccine manufactured in Italy, Moderna’s COVID-19 vaccine manufactured by Samsung Biologics, Pfizer’s oral COVID-19 treatment Paxlovid, and the COVID-19 injection Remdesivir for use in patients under 15 were approved using Kor
